MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

NCT06414148 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Large B-cell Lymphoma

Interventions

DRUG: Epcoritamab
DRUG: Epcoritamab, lenalidomide and rituximab

Sponsor

Peter MacCallum Cancer Centre, Australia

Collaborators

[object Object]